Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Arcutis Biotherapeutics, Inc. (ARQT)

32.07 +0.10 (+0.31%)
At close: October 30 at 4:00:01 PM EDT
31.82 -0.25 (-0.78%)
After hours: October 30 at 6:21:36 PM EDT
Trade ARQT on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Todd Franklin Watanabe M.A.
President, CEO & Director 1.31M -- 1968
Dr. Bhaskar Chaudhuri Ph.D.
Co-Founder & Director Emeritus 60.05k -- 1955
Ms. Latha Vairavan
Senior VP & Chief Financial Officer 644.9k -- 1978
Mr. Masaru Matsuda Esq., J.D.
Executive VP, Chief Legal Officer & Corporate Secretary 787.7k -- 1971
Dr. Patrick E. Burnett M.D., Ph.D.
Executive VP & Chief Medical Officer 883.38k 1.17M 1972
Mr. Brian Schoelkopf
Head of Investor Relations -- -- --
Mr. Steve Arias
Vice President of Compliance & Privacy -- -- --
Ms. Amanda Sheldon
Head of Corporate Communications -- -- --
Ms. Aleen Hosdaghian
Vice President of Marketing -- -- --
Mr. Todd Tucker
Senior VP & Chief Human Resources Officer -- -- --

Arcutis Biotherapeutics, Inc.

3027 Townsgate Road
Suite 300
Westlake Village, CA 91361
United States
805 418 5006 https://www.arcutis.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
354

Description

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Corporate Governance

Arcutis Biotherapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 4, 2026 at 9:00 PM UTC

Arcutis Biotherapeutics, Inc. Earnings Date

Recent Events

October 28, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 16, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 6, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 21, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

February 25, 2026 at 12:00 AM UTC

S-8: Offering Registrations

December 8, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

October 28, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

October 10, 2025 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: